On Jan. 29th, Sanofi-Aventis, a European pharmaceutical group and Large Shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), filed a Form 4 report...
Keep Reading →
January 29 - Insider Trading, News - Comments
Abrams Capital Management, led by David Abrams significantly trimmed its stake in Engility Holdings Inc (NYSE:EGL). According to a newly amended filing...
Keep Reading →
December 30 - Hedge Funds, News - Comments
To me, flu season is a lot like Christmas; there’s a defined time period when we expect it to occur, yet it seems to appear earlier and earlier...
Keep Reading →
September 23 - News - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best...
Keep Reading →
September 20 - News - Comments
Shares of drug delivery systems manufacturer Unilife Corp (NASDAQ:UNIS) recently rallied after it announced a long-term contract to sell prefilled syringes...
Keep Reading →
September 18 - News - Comments
There is perhaps nothing scarier than a cancer diagnosis. A study in 2010 conducted by Cancer Research UK demonstrated this to the “T,” when...
Keep Reading →
September 17 - News - Comments
More than anything, biotech companies need investors who are true believers in their products. In a sector more governed by future prospects than past...
Keep Reading →
September 17 - News - Comments
When you have $5.5 billion in your wallet, it’s understandable if there’s a hankering to spend some of it. French drugmaker Sanofi SA (ADR...
Keep Reading →
September 17 - News - Comments
In the world of small biotech companies, investors are always fishing for the next small fish to be gobbled up by a bigger one since the industry is well...
Keep Reading →
September 16 - News - Comments
Looking for the best-performing sector in this year’s big market rally? It may just be the biotech sector, which has erupted with astronomical gains...
Keep Reading →
September 16 - News - Comments
Think of The Motley Fool as kind of your TiVo for investment conferences. We’ll help you skip to the good parts and zip past all the rest. There...
Keep Reading →
September 15 - News - Comments
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case...
Keep Reading →
September 14 - News - Comments
In my opinion, the Nike+ FuelBand released by Apple Inc. (NASDAQ:AAPL) and NIKE, Inc. (NYSE:NKE) last year was a seminal product in health care tech...
Keep Reading →
September 11 - News - Comments
Unilife Corp (NASDAQ:UNIS) will release its quarterly report on Tuesday, but investors already have reason to believe that the company won’t make...
Keep Reading →
September 9 - News - Comments
Peregrine Pharmaceuticals (NASDAQ:PPHM) will release its latest quarterly report on Monday, and investors are under no illusions that the company will...
Keep Reading →
September 5 - News - Comments
As an investor in the health care sector, it can sometimes feel like everything — and everyone — is out to get you. The ongoing threat of...
Keep Reading →
August 30 - News - Comments
Allergan, Inc. (NYSE:AGN), the diversified health care giant best known for Botox, boasts an impressive portfolio of products. From the Lap-band surgical...
Keep Reading →
August 30 - News - Comments
In an attempt to further simplify its business and unlock shareholder value, Pfizer Inc. (NYSE:PFE) has been busy divesting itself of non-core assets...
Keep Reading →
August 29 - News - Comments
Eli Lilly & Co. (NYSE:LLY) recently rose nearly 3% following positive phase 3 results for cancer drug necitumumab. The company had previously halted...
Keep Reading →
August 27 - News - Comments
Peregrine Pharmaceuticals (NASDAQ:PPHM), a developmental stage biotech focusing on oncology treatments, recently announced that its lead drug candidate...
Keep Reading →
August 23 - News - Comments
Research into next-generation cholesterol drugs is picking up. Source: Wikimedia Commons. Once upon a time in a regulatory environment far, far away,...
Keep Reading →
August 21 - News - Comments
It’s a disease that doesn’t often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are...
Keep Reading →
August 19 - News - Comments
Earlier this year, in May, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was soaring on news of FDA approval of the Eylea injection. The market valued...
Keep Reading →
August 12 - News - Comments
August might be hot for most of the country, but the first full week of the month wasn’t so hot for some stocks. Here are some of the most horrendous...
Keep Reading →
August 12 - News - Comments
With the full implementation of the individual portion of the Patient Protection and Affordable Care Act less than five months away, physicians and doctor...
Keep Reading →
August 12 - News - Comments
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) closed Tuesday down over 6% following a second quarter report that missed estimates. A particular cause for...
Keep Reading →
August 9 - News - Comments
Note: This article has been amended to better reflect Lemtrada’s market position. Currently existing immunomodulatory drugs that treat Multiple...
Keep Reading →
August 8 - News - Comments
The Motley Fool’s readers have spoken, and I have heeded their cries. After months of pointing out CEO gaffes and faux pas, I’ve decided...
Keep Reading →
August 7 - News - Comments
As human beings it can sometimes be difficult for us to see the good in a bad situation. In the biotech sector, where developing a drug can cost hundreds...
Keep Reading →
August 7 - News - Comments
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits...
Keep Reading →
August 6 - News - Comments
Zoetis will release its quarterly report on Tuesday, and investors will get their first look at the company as a completely independent business entity...
Keep Reading →
August 5 - News - Comments
Around four in 10 Americans live in places where smog can impact their health. Children and teens are especially vulnerable to higher levels of ozone...
Keep Reading →
August 5 - News - Comments
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will release its quarterly report on Tuesday, and the company’s stock has been on an absolute tear over...
Keep Reading →
August 2 - News - Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday. Shares fell slightly as investors reacted...
Keep Reading →
August 1 - News - Comments
Diabetes is one of the world’s most dangerous and fastest-growing afflictions. According to the International Diabetes Federation, 366 million people...
Keep Reading →
August 1 - News - Comments
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)‘s recent earnings report is a key confirmation of a shifting market...
Keep Reading →
August 1 - News - Comments
It’s estimated that 30% to 40% of adults in the world experience some degree of insomnia every year. Most of these cases aren’t chronic and do not...
Keep Reading →
August 1 - News - Comments
Three months ago after Questcor Pharmaceuticals Inc (NASDAQ:QCOR) announced its first-quarter financial results, I asked if those results were as bad...
Keep Reading →
July 31 - News - Comments
We often take sleep, the number of hours we get to sleep, or the quality of sleep we get, for granted. However, that may not be such a wise idea, as insomnia...
Keep Reading →
July 29 - News - Comments
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow. This cancer can lead to abnormally high calcium levels...
Keep Reading →
July 26 - News - Comments
The “people familiar with the matter” are out in full force spouting off about who’s bidding for Onyx Pharmaceuticals, Inc. (NASDAQ...
Keep Reading →
July 19 - News - Comments
The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex. It’s...
Keep Reading →
July 19 - News - Comments
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy...
Keep Reading →
July 18 - News - Comments
Note: This version has been amended to better reflect Victoza’s dosage recommendations. At the American Diabetes Association meeting last month,...
Keep Reading →
July 12 - News - Comments
The Orphan Drug pipeline of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been growing so rapidly that the company has been the object of many takeover...
Keep Reading →
July 11 - News - Comments
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP...
Keep Reading →
July 10 - News - Comments
The U.S. military has a reputation as a somewhat secretive organization. But in one respect at least, the Pentagon ranks among our most transparent government...
Keep Reading →
July 8 - News - Comments
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don’t have to imagine...
Keep Reading →
July 5 - News - Comments
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016....
Keep Reading →
July 3 - News - Comments
Healthcare stocks have rallied over the past couple years, and for good reason. Not only is the global economy gaining traction, but the demographic trends...
Keep Reading →
June 28 - News - Comments